STOCK TITAN

[Form 4] Processa Pharmaceuticals, Inc. Common Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

EQT Corp (EQT) – Form 4 insider filing.

EVP Operations J.E.B. Bolen received an equity award of 26,620 restricted stock units (RSUs) on 07/25/2025, coded as an acquisition ("A") at $0 cost. Each RSU converts 1-for-1 into common stock and vests in three equal annual installments starting one year after the grant date. After the transaction, Bolen’s direct beneficial ownership rose to 70,787 shares, which includes accrued dividend equivalents. No open-market purchases, sales, or derivative trades were reported.

The filing reflects routine executive compensation designed to align management with shareholders; it does not materially alter insider control or signal a near-term view on EQT’s valuation.

EQT Corp (EQT) – Comunicazione interna Form 4.

Il vicepresidente esecutivo delle operazioni, J.E.B. Bolen, ha ricevuto un premio in azioni pari a 26.620 unità di azioni vincolate (RSU) il 25/07/2025, classificato come acquisizione ("A") a costo zero. Ogni RSU si converte 1:1 in azioni ordinarie e si consolida in tre rate annuali uguali a partire da un anno dopo la data di assegnazione. Dopo questa operazione, la proprietà diretta di Bolen è aumentata a 70.787 azioni, inclusi i dividendi maturati. Non sono state segnalate operazioni di acquisto, vendita o derivati sul mercato aperto.

La comunicazione riflette una normale politica di compensazione esecutiva volta ad allineare gli interessi del management con quelli degli azionisti; non modifica sostanzialmente il controllo interno né indica una valutazione a breve termine di EQT.

EQT Corp (EQT) – Presentación interna Formulario 4.

El vicepresidente ejecutivo de operaciones, J.E.B. Bolen, recibió una concesión de 26,620 unidades restringidas de acciones (RSU) el 25/07/2025, codificada como adquisición ("A") sin costo. Cada RSU se convierte 1 a 1 en acciones comunes y se consolida en tres cuotas anuales iguales comenzando un año después de la fecha de concesión. Tras la transacción, la propiedad directa de Bolen aumentó a 70,787 acciones, que incluye equivalentes de dividendos acumulados. No se reportaron compras, ventas o operaciones con derivados en el mercado abierto.

La presentación refleja una compensación ejecutiva rutinaria destinada a alinear la gestión con los accionistas; no altera materialmente el control interno ni indica una perspectiva a corto plazo sobre la valoración de EQT.

EQT Corp (EQT) – 내부자 신고서 Form 4 제출.

운영 담당 EVP J.E.B. Bolen은 2025년 7월 25일에 26,620개의 제한 주식 단위(RSU)를 무상 취득("A" 코드)하였습니다. 각 RSU는 1대1로 보통주로 전환되며, 부여일로부터 1년 후부터 3년에 걸쳐 매년 동일한 비율로 권리가 확정됩니다. 이번 거래 후 Bolen의 직접 소유 주식은 배당금 상응액을 포함하여 70,787주로 증가했습니다. 공개 시장에서의 매매나 파생상품 거래는 보고되지 않았습니다.

이 신고는 경영진 보상 정책의 일환으로, 경영진과 주주 간 이해관계 일치를 목적으로 하며, 내부자 지분에 중대한 변동을 주거나 EQT의 단기 가치 평가에 대한 신호를 나타내지 않습니다.

EQT Corp (EQT) – Déclaration d’initié Formulaire 4.

Le vice-président exécutif des opérations, J.E.B. Bolen, a reçu une attribution de 26 620 unités d’actions restreintes (RSU) le 25/07/2025, codée comme acquisition (« A ») sans coût. Chaque RSU se convertit en action ordinaire à raison de 1 pour 1 et se libère en trois versements annuels égaux à partir d’un an après la date d’attribution. Après cette opération, la détention directe de Bolen est passée à 70 787 actions, incluant les équivalents de dividendes accumulés. Aucune opération d’achat, de vente ou dérivée sur le marché ouvert n’a été signalée.

Cette déclaration reflète une rémunération exécutive courante visant à aligner la direction avec les actionnaires ; elle ne modifie pas significativement le contrôle interne ni n’indique une vision à court terme de la valorisation d’EQT.

EQT Corp (EQT) – Insider-Meldung Form 4.

EVP Operations J.E.B. Bolen erhielt am 25.07.2025 eine Zuteilung von 26.620 Restricted Stock Units (RSUs), codiert als Erwerb ("A") ohne Kosten. Jede RSU wird 1:1 in Stammaktien umgewandelt und wird in drei gleichen jährlichen Tranchen beginnend ein Jahr nach dem Zuteilungsdatum unverfallbar. Nach der Transaktion stieg Bolens direkte wirtschaftliche Eigentümerschaft auf 70.787 Aktien, einschließlich aufgelaufener Dividendenäquivalente. Keine Käufe, Verkäufe oder Derivategeschäfte am offenen Markt wurden gemeldet.

Die Meldung spiegelt eine routinemäßige Vergütung der Geschäftsführung wider, die darauf abzielt, das Management mit den Aktionären in Einklang zu bringen; sie ändert die Insiderkontrolle nicht wesentlich und signalisiert keine kurzfristige Einschätzung der EQT-Bewertung.

Positive
  • Insider stake increases by 26,620 shares, reinforcing management–shareholder alignment.
Negative
  • None.

Insights

TL;DR: Routine RSU grant; modest ownership increase; minimal market impact.

The award adds roughly 0.02% to EQT’s 370 mn share count, so dilution is negligible. Insider acquisitions are generally viewed favorably, but because this is a zero-cost compensation grant rather than an open-market buy, it provides limited incremental insight into management’s conviction. Vesting over three years supports retention and long-term alignment. No red flags—no sales, hedging, or complex derivatives—so the filing is neutral from a valuation and governance standpoint.

EQT Corp (EQT) – Comunicazione interna Form 4.

Il vicepresidente esecutivo delle operazioni, J.E.B. Bolen, ha ricevuto un premio in azioni pari a 26.620 unità di azioni vincolate (RSU) il 25/07/2025, classificato come acquisizione ("A") a costo zero. Ogni RSU si converte 1:1 in azioni ordinarie e si consolida in tre rate annuali uguali a partire da un anno dopo la data di assegnazione. Dopo questa operazione, la proprietà diretta di Bolen è aumentata a 70.787 azioni, inclusi i dividendi maturati. Non sono state segnalate operazioni di acquisto, vendita o derivati sul mercato aperto.

La comunicazione riflette una normale politica di compensazione esecutiva volta ad allineare gli interessi del management con quelli degli azionisti; non modifica sostanzialmente il controllo interno né indica una valutazione a breve termine di EQT.

EQT Corp (EQT) – Presentación interna Formulario 4.

El vicepresidente ejecutivo de operaciones, J.E.B. Bolen, recibió una concesión de 26,620 unidades restringidas de acciones (RSU) el 25/07/2025, codificada como adquisición ("A") sin costo. Cada RSU se convierte 1 a 1 en acciones comunes y se consolida en tres cuotas anuales iguales comenzando un año después de la fecha de concesión. Tras la transacción, la propiedad directa de Bolen aumentó a 70,787 acciones, que incluye equivalentes de dividendos acumulados. No se reportaron compras, ventas o operaciones con derivados en el mercado abierto.

La presentación refleja una compensación ejecutiva rutinaria destinada a alinear la gestión con los accionistas; no altera materialmente el control interno ni indica una perspectiva a corto plazo sobre la valoración de EQT.

EQT Corp (EQT) – 내부자 신고서 Form 4 제출.

운영 담당 EVP J.E.B. Bolen은 2025년 7월 25일에 26,620개의 제한 주식 단위(RSU)를 무상 취득("A" 코드)하였습니다. 각 RSU는 1대1로 보통주로 전환되며, 부여일로부터 1년 후부터 3년에 걸쳐 매년 동일한 비율로 권리가 확정됩니다. 이번 거래 후 Bolen의 직접 소유 주식은 배당금 상응액을 포함하여 70,787주로 증가했습니다. 공개 시장에서의 매매나 파생상품 거래는 보고되지 않았습니다.

이 신고는 경영진 보상 정책의 일환으로, 경영진과 주주 간 이해관계 일치를 목적으로 하며, 내부자 지분에 중대한 변동을 주거나 EQT의 단기 가치 평가에 대한 신호를 나타내지 않습니다.

EQT Corp (EQT) – Déclaration d’initié Formulaire 4.

Le vice-président exécutif des opérations, J.E.B. Bolen, a reçu une attribution de 26 620 unités d’actions restreintes (RSU) le 25/07/2025, codée comme acquisition (« A ») sans coût. Chaque RSU se convertit en action ordinaire à raison de 1 pour 1 et se libère en trois versements annuels égaux à partir d’un an après la date d’attribution. Après cette opération, la détention directe de Bolen est passée à 70 787 actions, incluant les équivalents de dividendes accumulés. Aucune opération d’achat, de vente ou dérivée sur le marché ouvert n’a été signalée.

Cette déclaration reflète une rémunération exécutive courante visant à aligner la direction avec les actionnaires ; elle ne modifie pas significativement le contrôle interne ni n’indique une vision à court terme de la valorisation d’EQT.

EQT Corp (EQT) – Insider-Meldung Form 4.

EVP Operations J.E.B. Bolen erhielt am 25.07.2025 eine Zuteilung von 26.620 Restricted Stock Units (RSUs), codiert als Erwerb ("A") ohne Kosten. Jede RSU wird 1:1 in Stammaktien umgewandelt und wird in drei gleichen jährlichen Tranchen beginnend ein Jahr nach dem Zuteilungsdatum unverfallbar. Nach der Transaktion stieg Bolens direkte wirtschaftliche Eigentümerschaft auf 70.787 Aktien, einschließlich aufgelaufener Dividendenäquivalente. Keine Käufe, Verkäufe oder Derivategeschäfte am offenen Markt wurden gemeldet.

Die Meldung spiegelt eine routinemäßige Vergütung der Geschäftsführung wider, die darauf abzielt, das Management mit den Aktionären in Einklang zu bringen; sie ändert die Insiderkontrolle nicht wesentlich und signalisiert keine kurzfristige Einschätzung der EQT-Bewertung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Lin Patrick

(Last) (First) (Middle)
C/O PROCESSA PHARMACEUTICALS, INC.
601 21ST STREET SUITE 300

(Street)
VERO BEACH FL 32960

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Business - Strategy Off
3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0 07/24/2025 A 1,401,650(1) (2) (2) Common Stock 1,401,650 $0 1,412,082 D
Explanation of Responses:
1. Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 1,384,411 shares are subject to stockholder approval of the revised Omnibus Plan.
2. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028.
/s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact 07/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many EQT shares did EVP J.E.B. Bolen acquire?

He was granted 26,620 restricted stock units on 07/25/2025.

What is Bolen’s total EQT ownership after the grant?

His direct beneficial ownership rose to 70,787 common shares.

Were any EQT shares sold by the insider?

No. The Form 4 reports only an acquisition; no sales were disclosed.

What is the vesting schedule for the RSUs?

The RSUs vest in three equal annual installments beginning one year after the grant date.

Does this filing affect EQT’s share count materially?

The award is immaterial relative to EQT’s >300 mn shares outstanding, so dilution is negligible.
Processa Pharmaceuticals Inc

NASDAQ:PCSA

PCSA Rankings

PCSA Latest News

PCSA Latest SEC Filings

PCSA Stock Data

6.06M
23.15M
5.71%
2.09%
2.81%
Biotechnology
Pharmaceutical Preparations
Link
United States
HANOVER